Skip to main content

Table 2 Patients' clinical progress before and after treatment of LQF

From: LuQi Formula relieves ventricular remodeling through improvement of HIF-1α-mediated intestinal barrier integrity

Parameters

Before treatment

After treatment

P-value

LVEF (%)

45.53 ± 3.009

58.47 ± 1.289

 < 0.0001***

LVFS (%)

23.41 ± 1.833

31.53 ± 0.8275

 < 0.0001***

LVSV (logmL)

1.807 ± 0.04616

1.922 ± 0.03816

0.0195*

LVEDV (logmL)

2.198 ± 0.04086

2.149 ± 0.04484

0.1731

LVESV (logmL)

1.931 ± 0.0611

1.814 ± 0.04487

0.0560

ALT (U/L)

25.18 ± 2.801

22.38 ± 1.839

0.2670

AST (U/L)

24.5 ± 1.966

22.38 ± 1.363

0.2399

Carbamide (mmol/L)

6.831 ± 0.4997

7.278 ± 0.5945

0.5486

Creatinine (μmol/L)

89.4 ± 4.841

87.59 ± 6.965

0.7522

BNP (pg/mL)

701.6 ± 109.5

381.8 ± 99.67

0.0002***

LPS (EU/mL)

2.331 ± 0.06663

1.674 ± 0.03716

 < 0.0001***

D-lactate (μg/L)

533.5 ± 52.85

394.8 ± 52.62

 < 0.0001***

zonulin (ng/L)

444.5 ± 19.49

389.3 ± 17.31

 < 0.0001***

  1. All experimental data are expressed as mean ± standard deviation, * p < 0.05, *** p < 0.001 compared with before treatment. n = 17
  2. LVEF left ventricular ejection fraction; LVFS left ventricular fractional shortening; LVSV left ventricular stroke volume; LVEDV left ventricular end-diastolic dimension; LVESV left ventricular end-systolic dimension; ALT Alanine transaminase; AST Aspartate aminotransferase; BNP brain natriuretic peptide; LPS endotoxin
Back to article page

Chinese Medicine

ISSN: 1749-8546

Contact us